Avamys (fluticason furoat)

Conclusion

Fluticasone has been on the market for many years as fluticasone-propionate. A new derivate of fluticasone, fluticasone-furoate, is marketed as Avamys.

There hasn’t been made any comparative studies between fluticason-furoate nasal spray and other nasal corticosteroids.

Fluticasone-furoate has in a study of children and adults shown improved symptoms in allergic rhinitis and life quality to higher extent than placebo. The incipient effect started 8 hours after administration.

Fluticasone-furoate induce side effects at placebo level except epitaxis, that can be found in approximately 20 % of the treated against 8 % in the placebo group.

Fluticasone-furoate is approximately at the same price level as other nasal corticosteroids.

Fluticasone-furoate was marketed the 24th of March 2008.